Gyre Therapeutics Profit Margin

Gyre Therapeutics (GYRE) currently reports a profit margin of -10.62% as of June 2026. That compares with 10.65% in the prior-year period — down 199.7% year over year. That is below the Healthcare sector average of 13.76%. Use the charts on this page to explore Gyre Therapeutics's profit margin history and peer comparisons.

Gyre Therapeutics's profit margin decreased from 10.65% to -10.62% — a 199.7% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Gyre Therapeutics's profit margin of -10.62% is lower than the Healthcare sector average of 13.76%. That is roughly 177.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Gyre Therapeutics's current -10.62% should be judged against Healthcare norms (sector average: 13.76%) and against GYRE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -10.62%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.76%. From there, open related valuation or income-statement pages for Gyre Therapeutics, and consider following GYRE for alerts when major investors trade the stock.